Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo-Jack, Nathaniel J. Myall, Georg Richtig, Jillian W. P Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R. Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A. Sosman, Scott Kopetz, Vivek Subbiah, Michael A. Davies, Anna Groover, Ryan J. Sullivan, Keith T. Flaherty, Douglas B. Johnson, Andrea Benedetti, David W. Cescon, Anna Spreafico, George Zogopoulos, April A. N. Rose
medRxiv 2022.02.17.22271120; doi: https://doi.org/10.1101/2022.02.17.22271120